This article is originally published in PharmaPhorum.
As we move forwards in public discussions on pharmaceutical innovation and its value to patients and society, it is helpful to ground conversations in a solid understanding of how medicines development occurs.
CRA’s Life Sciences Practice team along with experts at The Janssen Pharmaceutical Companies of Johnson & Johnson recently conducted a landscape review of how complex pharmaceutical innovation happens in practice, leveraging three therapy area case studies: HIV/AIDS, multiple sclerosis, and multiple myeloma. This article is the first of two parts.
Click here to read more.
